Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice

Ketty Peris, Piergiacomo Calzavara Pinton, Lisa Licitra, Armando Santoro, Paolo Antonio Ascierto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity due to its location on the face, its frequency of relapse and its capacity to invade local tissues. The primary treatment of BCC usually involves surgery or radiotherapy. In patients who have exhausted surgical and radiotherapy options or with metastatic BCC, guidelines recommend the use of the Hedgehog pathway inhibitor vismodegib. This molecule is indicated for the treatment of adults with metastatic BCC, or with locally advanced BCC which has recurred following surgery or who are not eligible to surgery or radiation. This paper aims to provide suggestions on the optimal management of BCC patients treated with vismodegib in clinical practice, according to the large experience gained by a group of Italian dermatologists and oncologists. In particular, the focus of this paper will be on the monitoring of patients and the management of adverse events.
Lingua originaleEnglish
pagine (da-a)1429-1435
Numero di pagine7
RivistaFuture Oncology
Volume11
DOI
Stato di pubblicazionePubblicato - 2015

Keywords

  • adverse events
  • basal cell carcinoma
  • clinical practice
  • vismodegib

Fingerprint

Entra nei temi di ricerca di 'Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice'. Insieme formano una fingerprint unica.

Cita questo